Tag: Targeted therapy for CRC

Home / Targeted therapy for CRC

Categories

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
targeted-therapy-for-crc

We Are Online! Chat With Us!
Scan the code